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Background: The darunavir genotypic inhibitory quotient (gIQ) has been suggested as one of the predictors of
virological response to darunavir-containing salvage regimens. Nevertheless, which resistance algorithm should
be used to optimize the calculation of gIQ is still debated. The aim of our study was to compare seven different
free-access resistance algorithms and their derived gIQs as predictors of 48 week virological response to
darunavir-based salvage therapy in the clinical setting.
Methods: Patients placed on two nucleoside reverse transcriptase inhibitors+600/100 mg of darunavir/ritona-
vir twice daily+enfuvirtide were prospectively evaluated. Virological response was assessed at 48 weeks.
Darunavir resistance interpretation was performed according to seven different algorithms, of which two
were weighted algorithms. Analysis of other factors potentially associated with virological response at
48 weeks was performed.
Results: Fifty-six treatment-experienced patients were included. Overall, 35 patients (62.5%) had a virological
response at 48 weeks. Receiver operator characteristic curve analysis showed that De Meyer’s weighted score
(WS) and its derived gIQ (gIQ WS) were the most accurate parameters defining virological response, and
related cut-offs showed the best sensitivity/specificity pattern. In univariate logistic regression analysis,
baseline log viral load (P¼0.028), optimized background score ≥2 (P¼0.048), WS .5 (P¼0.001) and WS
gIQ ≥600 (P,0.0001) were independently associated with virological response. In multivariate analysis,
only baseline log viral load (P¼0.008) and WS gIQ ≥600 (P,0.0001) remained in the model.
Conclusions: In our study, although different resistance interpretation algorithms and derived gIQs were
associated with virological response, gIQ WS was the most accurate predictive model for achieving a successful
virological response.
Keywords: weighted scores, protease inhibitors, HIV
Introduction
Darunavir is the most recently licensed protease inhibitor with
in vitro activity against both wild-type and protease inhibitor-
resistant HIV-1 isolates. Darunavir showed efficacy in patients
in whom multiple protease inhibitor-containing regimens
failed.1,2 Modelling and crystallographic studies of the HIV-1 pro-
tease have demonstrated unusual darunavir binding character-
istics that predict greater resilience to the development of
resistance and greater activity against resistant viruses than
earlier protease inhibitors.1,3 – 6 In vitro selection of darunavir-
resistant HIV-1 from wild-type strains appears to be slower
and less frequent than with other protease inhibitors,1,5 reflect-
ing the particularly strong binding of darunavir to the HIV
protease.3,6
The efficacy of ritonavir-boosted darunavir in combination
with an optimized background regimen has been studied in
highly treatment-experienced HIV-infected patients in two
Phase IIb trials, in which virological and immunological efficacy
were superior to the control group.2,7 – 10
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The number of active drugs included in the antiretroviral
regimen and the degree of viral resistance to darunavir are
factors associated with virological and immunological responses
in patients undergoing darunavir-based salvage therapy.7,11 – 15
The usefulness of a genotypic resistance test for the prediction
of virological response to darunavir has been widely studied,
and several amino acid changes in the protease gene have
been associated with higher rates of virological failure.11 Baseline
darunavir phenotypic resistance and the phenotypic inhibitory
quotient (IQ) appeared to be predictive of virological
outcome.11,14 Moreover, the darunavir virtual IQ has been
shown to predict virological response to darunavir-based
salvage therapy better than trough concentration (Ctrough) or
resistance mutations considered separately.16
The genotypic IQ (gIQ), calculated as the ratio between pro-
tease inhibitor Ctrough and the number of protease inhibitor-
associated mutations, is simpler to derive in the clinical setting
than the virtual IQ or phenotypic IQ and has been associated
with virological response to other protease inhibitors.17 – 21
Three studies consensually showed a relationship between the
darunavir gIQ and virological response,16,22,23 although this
association appeared to be mainly driven by the number of
mutations. However, in our opinion, the darunavir gIQ has not
been fully evaluated in the clinical setting. In previous studies,
in fact, all mutations were equally weighted in the calculation
of the darunavir gIQ, while the use of weighted mutation
scores could optimize the predictivity and reliability of the latter.
Therefore, our aim was to explore the impact of seven differ-
ent resistance interpretation algorithms and their derived gIQs
on 48 week virological response to darunavir-based salvage regi-
mens in clinical practice.
Patients and methods
Study design
Patients enrolled in the darunavir Expanded Access Program study in two
different centres in northern Italy from May 2006 to August 2008, and
treated with a regimen based on 600/100 mg of darunavir/ritonavir
twice daily plus an optimized background regimen, were prospectively
evaluated. The criteria for inclusion were baseline plasma HIV-RNA
.50 copies/mL, HIV genotypic resistance test performed in the last
3 months before initiation of darunavir-based regimen, regular follow-up,
availability of at least one darunavir plasma concentration measurement,
and self-reported adherence of .90% in the last 7 days before each visit.
Viral load and CD4+ cell count were assayed by RT–PCR (Cobas Amplicor
HIV-1 monitor test v 1.5, Roche Molecular Systems, Switzerland) and flow
cytometry, respectively, at baseline and at 4, 12, 24 and 48 weeks. This
study was performed in the context of the Expanded Access Program
for darunavir, so ethics approval was obtained from the local ethics com-
mittee in the context of patient inclusion in this study. The only test not
considered for routine monitoring was the therapeutic drug monitoring.
For this test, informed consent was obtained from patients at each visit.
Study endpoints
The primary virological response endpoint was reaching complete viral
load suppression (,50 copies/mL). Additionally, significant antiviral
activity was considered if viral load decreased by ≥1 log and/or the
patient achieved ,50 copies/mL HIV-RNA with no viral load increase
.0.5 log as compared with the maximal viral load decrease. Immuno-
logical response at each timepoint was also studied. The Intention to
Treat Last Observation Carried Forward method was used. In this
approach, for subjects who discontinued darunavir before week 48, the
last HIV-RNA and CD4+ cell count recorded before darunavir withdrawal
were considered for further analysis.
Genotypic resistance test
A genotypic resistance test was performed at baseline by using the
ViroSeq HIV-1 Genotyping System (Celera Diagnostics, LCC, Alameda,
CA, USA) with an automatic sequencer (ABI PRISM 3100, PE Biosystems,
Foster City, CA, USA). FASTA analysis of the reverse transcriptase (amino
acids 1–335) and protease (amino acids 1–99) genes was conducted
using the Stanford HIVdb Program (http://hivdb.stanford.edu/, accessed
on 24 July 2009). Specific mutations in the protease gene were obtained
from the Stanford HIVdb report, and genotypic darunavir resistance
interpretation was performed according to seven different algorithms:
the HIVdb—weighted interpretation algorithm (http://hivdb.stanford.
edu/, accessed on 24 July 2009); the weighted mutation score (WS) pro-
posed by De Meyer et al.24 (V11I, I54L/M, G73S and L89V, score 1; V32I,
L33F and I47V, score 3; L76V and I84V, score 4; and I50V, score 5); the
National Agency for AIDS Research resistance algorithm (ANRS) (http://
www.hivfrenchresistance.org/, accessed on 15 October 2009); the
number of darunavir resistance mutations derived from the POWER
trials (POW);11 the number of primary protease inhibitors resistance
mutations from the last International AIDS Society (IAS) list update;25
the total number of mutations associated with resistance to protease
inhibitors in the IAS list;25 and the genotypic score calculated in the
PREDIZISTA study.22
Calculation of the optimized background score (OBS)
The OBS was calculated by relying on the genotypic sensitivity score pro-
vided by the Stanford HIVdb Program (http://hivdb.stanford.edu/,
accessed on 24 July 2009). The FASTA sequence was submitted and a
resistance score for each companion drug was obtained. A drug resist-
ance estimate for the latter was obtained by summing the scores of
each mutation associated with resistance to such drug. A drug was con-
sidered to be not active with a score of ≥60. Drugs reported to be active
or partially active (,60) were scored as 1, while drugs reported to be not
active (≥60) were scored as 0. The OBS was defined as the sum of the
scores of all the drugs included in the regimen. In subjects administered
with enfuvirtide, this drug was considered to be not active if previously
administered to the subject and discontinued due to virological failure.
Pharmacokinetic analysis
Blood samples were collected into lithium heparin tubes before the
morning dose, and plasma was separated by centrifugation at
5000 rpm, refrigerated at 48C for 10 min and then stored at 2708C
until analysis. At the time of blood sampling, patients were asked
about the time of their last darunavir dose intake. Only plasma
samples obtained 10–14 h post-dose were considered for Ctrough analy-
sis. Darunavir concentrations were determined by using a validated
HPLC method with UV detection.26 In subjects with more than one phar-
macokinetic measurement, the mean value of all available Ctrough values
throughout the study period was considered. The gIQ values were calcu-
lated for each patient as the ratios between mean darunavir Ctrough and
the scores derived from the seven different algorithms considered.
Statistical analyses
Receiver operator characteristic (ROC) curve analysis was used to dis-
criminate between the different interpretation algorithms and their
derived gIQs. ROC curve analysis was used to determine cut-off values
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for those parameters significantly associated with virological response at
48 weeks. The area under the curve (AUC) of ROC, sensitivity, specificity,
positive predictive value (PPV), negative predictive value (NPV), likelihood
ratio positive [LHR+; calculated as sensitivity/(12specificity)] and likeli-
hood ratio negative [LHR2; calculated as (12sensitivity)/specificity]
were analysed for the selection of the best resistance algorithm and
gIQ. Overall, the best predictors were those with the highest LHR+ and
the lowest LHR2. Once identified, it was included in a logistic regression
model with all the other baseline characteristics potentially correlated
with virological response at 48 weeks. Variables showing P values of
,0.05 in univariate analysis were considered for multivariate analysis
(forward conditional method). Survival analysis was performed by
Kaplan–Meier analysis with the log rank test as the comparison factor.
The x2 test was used to analyse the association between categorical
variables. Statistical significance was considered at P,0.05. Statistical
analysis was performed using SPSS software (2004, version 13.0, SPSS
Inc., Chicago, IL, USA).
Results
Baseline patient characteristics
Baseline characteristics of the 56 patients included in this study
are reported in Table 1. Median (range) numbers of previous
nucleoside reverse transcriptase inhibitors and non-nucleoside
reverse transcriptase inhibitors were 5 (2–6) and 1 (0–2),
respectively. Subjects had previous failures to a median (range)
of 4 (1–7) protease inhibitor-based regimens.
The nucleoside reverse transcriptase inhibitors most fre-
quently co-administered with darunavir/ritonavir were
tenofovir (n¼38, 67.9%), emtricitabine (n¼29, 51.8%) and lami-
vudine (n¼20, 35.7%). Tenofovir and emtricitabine were co-
administered in 23 (41.1%) subjects. Other antiretroviral drugs
co-administered with darunavir/ritonavir were zidovudine
(n¼15, 26.8%), abacavir (n¼8, 14.3%), stavudine (n¼8,
14.3%), didanosine (n¼5, 8.9%), zalcitabine (n¼2, 3.6%)
and etravirine (n¼7, 12.5%). Enfuvirtide was administered to
18 (32.1%) subjects, of whom only 2 were enfuvirtide-
experienced and had previous virological failure with a regimen
including this drug.
The optimized background regimen included a median
(range) of 3 (2–4) drugs, of which 2 (0–3) were considered
active. Seven subjects (12.5%) had no active drugs in the opti-
mized background regimen, 18 (32.1%) had one active drug
and 31 (55.4%) had two or more active drugs.
Virological and immunological outcomes
The median [interquartile range (IQR)] log HIV-RNA and CD4+
cells at baseline were 3.95 (2.95–4.93) log and 265 (124–388)
cells/mm3. The median (IQR) CD4+ cell count increases were 36
(7–99), 52 (22–139), 90 (15–140) and 83 cells/mm3 (33–181)
at 4, 12, 24 and 48 weeks, respectively. Median (IQR) plasma
HIV-RNA decrease was 21.92 (22.53 to 21), –1.88 log (22.66
to 20.89), 21.71 log (22.69 to 20.65) and 21.38 log (22.69 to
20.62) at 4, 12, 24 and 48 weeks, respectively. Complete viral sup-
pression below 50 copies/mL was observed in 26 (46.4%), 29
(51.8%), 34 (60.7%) and 35 (62.5%) subjects at 4, 12, 24 and
48 weeks, respectively. Significant antiviral activity was observed
in 49 (87.5%), 43 (76.8%), 38 (67.9%) and 35 (62.5%) subjects
Table 1. Demographics and baseline characteristics of the study
population
Total population
Total number of patients 56
Sex (male)a 44 (78.6)
Age (years)b 45 (42–50)
Weight (kg)b 69 (58–75)
Height (cm)b 175 (168–180)
HCV co-infectiona 17 (30.4)
Clinical status (CDC 1993 classification)a
A 29 (51.8)
B 9 (16.1)
C 18 (32.1)
Pharmacological history
no. of previous PIsc 5 (2–7)
no. of PIs with virological failure 4 (1–7)
no. of previous NRTIsc 5 (2–6)
no. of NRTIs with virological failure 5 (0–6)
previous TDFa 54 (96.43)
TDF with virological failure 25/54 (46.3)
no. of previous NNRTIsc 1 (0–2)
no. of NNRTIs with virological failure 1 (0–2)
previous enfuvirtidea 28 (50)
OB regimen
no. of drugs in OB regimenc 3 (2–4)
OB regimen with enfuvirtidea 18 (32.14)
no. of subjects with previous
virological failure to enfuvirtide
2/18 (11.1)
no. of drugs in OB considered to be
active (OBS)c distribution of OBSa
2 (0–3)
0a 7 (12.5)
1a 18 (32.1)
2a 24 (49.2)
3a 7 (12.5)
Baseline immuno-virology
log HIV-RNAb 3.95 (2.95–4.93)
CD4+ cells/mLb 265 (124–388)
CD4+%b 15.1 (14–22)
NRTIs, nucleoside reverse transcriptase inhibitors; NNRTIs, non-
nucleoside reverse transcriptase inhibitors; PIs, protease inhibitors; TDF,
tenofovir disoproxil fumarate; OB, optimized background; OBS,
optimized background score; IQR, interquartile range; HCV, hepatitis C
virus.
aValues are expressed as number of subjects (%).
bValues are expressed as median (IQR).
cValues are expressed as median (range).
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at 4, 12, 24 and 48 weeks, respectively. Three (5.35%) subjects
never had significant antiviral activity and 18 (32.14%) subjects
had significant antiviral activity during the follow-up period, but
this was not sustained. According to the OBS, complete viral sup-
pression at 48 weeks was observed in 2/7 (28.5%), 10/18 (55.5%)
and 23/31 (74.2%) of subjects with an OBS of 0, 1 and≥2, respect-
ively (x2¼5.6, P¼0.06). No differences in virological response or
viral load decrease at 48 weeks were observed according to enfu-
virtide administration. In fact, virological response at 48 weeks
was observed in 12/18 subjects treated with enfuvirtide,
whereas it was observed in 23/38 without enfuvirtide
(x2¼0.196, P¼0.658). Viral load decrease in subjects adminis-
tered with enfuvirtide was 21.92+1.32 versus 21.52+1.35
without enfuvirtide (P¼0.658). No differences in the number of
darunavir-associated resistance mutations or gIQs were
observed, but a higher number of active drugs were administered
in the enfuvirtide arm (2 versus 1, P¼0.001). Nevertheless, the
increase in the CD4+ cell count and percentage at this timepoint
was higher in the enfuvirtide group [88+156 versus
165+139 cells/mm3 (P¼0.08) and 2.6+3.47 versus
4.4+4.1 cells/mm3 (P¼0.15), respectively], although this differ-
ence was not statistically significant.
Pharmacokinetic analysis
A total of 188 plasma samples were collected for pharmacoki-
netic analysis. A median (IQR) of 4 (2–4) samples were obtained
from each subject. The mean (+SD) darunavir Ctrough was
4720+2380 ng/mL (n¼43), 3666+1987 ng/mL (n¼41),
4836+2249 ng/mL (n¼41) and 4421+2182 ng/mL (n¼28) at
4, 12, 24 and 48 weeks, respectively. The overall mean (+SD)
of all available darunavir Ctrough measurements through
48 weeks was 4561 (+1933) ng/mL. The intra- and inter-
individual variability (CV%, SD/mean×100) of the darunavir
Ctrough were 29.6% and 47.5%, respectively. Although the daru-
navir Ctrough was higher in the virological response group
(4913+1990 versus 3974+1722 ng/mL), this difference was
not statistically significant (P¼0.078).
Analysis of resistance interpretation algorithms and
their derived gIQs for the prediction of 48 week
virological response
Specific amino acid changes in the protease gene are presented
in Figure 1. In ROC curve analysis, WS and WS gIQ were the most
accurate parameters defining virological response (AUC¼0.797
and AUC¼0.848, respectively), and calculated cut-offs showed
that these resistance interpretation algorithms had the best sen-
sitivity/specificity profile (WS .5, sensitivity 77.1%/specificity
81%; and WS gIQ ≥600, sensitivity 82.9%/specificity 85.7%),
the highest LHR+ (4.06 and 5.79, respectively) and the lowest
LHR2 (0.28 and 0.19). Results of the different HIV-1 resistance
algorithms and their derived gIQs are presented in Table 2.
Twenty-seven out of 31 (87.1%) subjects with WS ≤5 showed
virological response, whereas it was achieved in only 8/25
(32%) with WS .5 (x2¼17.9, P¼0.001). In the same way, 29/
32 (90.65%) subjects with a darunavir WS gIQ ≥600 achieved
virological response, whereas it was recorded in only 6/24
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Figure 1. Frequency of specific amino acid changes at specific codons in the protease gene. Black bars represent amino acid changes associated with
darunavir resistance mutations in the POWER studies.
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(25%) subjects with a darunavir WS gIQ ,600 (x2¼25.2,
P,0.0001).
Determinants of virological response at 48 weeks
Baseline factors potentially associated with virological response
to darunavir-based regimens were analysed by using logistic
regression analysis. In univariate logistic regression analysis,
baseline viral load (P¼0.028), OBS ≥2 (P¼0.048), WS .5
(P¼0.001) and WS gIQ ≥600 (P,0.0001) were shown to be
independently associated with virological response. In multi-
variate analysis, baseline viral load (P¼0.008) and WS gIQ
≥600 (P,0.0001) remained in the model as predictors of virolo-
gical response at 48 weeks. The results of logistic regression
analysis are reported in Table 3. Kaplan–Meier survival analysis
(Figure 2) showed that subjects with WS gIQ ,600
(log rank¼17.95, P,0.0001) and with WS .5 (log
rank¼10.35, P¼0.001) were more likely to have virological
failure.
Analysis of the different virological response patterns
Three different patterns of virological response were observed in
our population: the null response group (n¼3), when significant
antiviral activity was not reached at any time during the study;
Table 3. Summary results of logistic regression analysis; virological
response at 48 weeks was considered as a dependent variable, whereas
variables listed in the first column of the table were tested as
independent variables.
Univariate analysis
P value
Multivariate analysis
P value
Baseline log viral load 0.028 0.008
Baseline CD4+ cell
count
0.171
OBS ≥2 0.048 NS
Previous no. of PIs 0.77
ENF administration 0.658
ETV administration 0.204
TDF administration 0.461
CDC stage 0.564
Darunavir Ctrough 0.089
gIQ WS ≥600 ,0.0001 ,0.0001
WS .5 0.001 NS
PI, protease inhibitor; ENF, enfuvirtide; ETV, etravirine; TDF, tenofovir
disoproxil fumarate; NS, not significant; OBS, optimized background
score; WS, weighted score; gIQ, WS genotypic inhibitory quotient.
Table 2. ROC curve analysis of the seven resistance interpretation algorithms
Median value (IQR)
ROC curve analysis
AUC P value cut-off sensitivity (%) specificity (%) PPV (%) NPV (%) LHR+ LHR2
Mutation score
WS 4.5 (3–7) 0.797 0.001 .5 77.1 81 87.1 68 4.06 0.28
ST 33 (28–47) 0.763 0.001 .37 71.42 71.47 80.64 60 2.5 0.39
POW 2 (1–3) 0.783 ,0.0001 .2 88.6 57.1 77.5 75 2.06 0.2
ANRS 1.5 (1–3) 0.783 ,0.0001 .2 88.57 47.6 73.8 71.4 1.69 0.2
PRIMs 4 (3–5) 0.655 0.054 — — — — — — —
TOTIAS 12 (11–13) 0.543 0.594 — — — — — — —
PRED 4 (2–4) 0.544 0.588 — — — — — — —
gIQ
WS 888 (473–1728) 0.848 ,0.0001 ≥600 82.9 85.7 90.62 75 5.79 0.19
STAN 113 (82.5–204) 0.809 ,0.0001 .106 80 85.7 90.32 72 5.59 0.23
POW 2584 (1355–4350) 0.826 ,0.0001 .2100 80 85.7 87.8 73.9 4.35 0.21
ANRS 2681 (1473–4402) 0.824 ,0.0001 .2200 82.9 85.7 90.6 75 5.79 0.19
PRIMs 1128 (795–1967) 0.738 0.003 .1100 68.6 76.4 82.75 59.25 2.88 0.41
TOTIAS 349 (272–493) 0.684 0.022 .350 60 71.4 77.7 51.7 2.09 0.56
PRED 1440 (920–2375) 0.614 0.158 — — — — — — —
AUC, area under the curve; PPV, positive predictive value; NPV, negative predictive value; LHR+, likelihood ratio positive; LHR2, likelihood ratio negative;
gIQ, genotypic inhibitory quotient.
WS, weighted score (V11I, I54L/M, G73S and L89V, score 1; V32I, L33F and I47V, score 3; L76V and I84V, score 4; and I50V, score 5).
ST, HIVdb—Stanford University genotypic resistance interpretation algorithm (http://hivdb.stanford.edu/).
POW, power mutation score (V11I, V32I, L33F, I47V, I50V, I54L/M, G73S, L76V, I84V and L89V).
ANRS, National Agency for AIDS Research resistance algorithm (V11I, V32I, L33F, I47V, I50V, I54L/M, T74P, L76V, I84V and L89V).
PRIMs, protease inhibitor primary resistance mutations from the IAS list [30N, 32I, 33F, 46 I/L, 47 V/A, 48V, 54 L/M, 58E, 74P, 82 A/T/F/S, 88S and
90M9].
TOTIAS, total number of protease inhibitor-associated resistance mutations from the IAS list.9
PRED, PREDIZISTA study score (I13V, V32I, L33F/I/V, E35D, M361/L/V, I47V, F53L and I62V).
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the partial response group (n¼18), when significant antiviral
activity was reached at any time during the study, but viral
load increased by .0.5 log at the end of the study; and the
full response group (n¼35), when significant antiviral activity
was reached at any time during the study and was maintained
at the end of the study. Differences in the main factors affecting
the antiviral activity according to the virological response pattern
are presented in Table 4. Overall, higher gIQ WS and lower
number of darunavir-associated resistance mutations, according
to the POWER study algorithm, were observed in the full
response group compared with the null response and partial
response groups. Moreover, the partial response group had a
higher WS (7.5+2.6, 83.3% with WS .5) and baseline viral
load (4.57 log), and a low OBS (33.3% OBS ≥2). In this group,
the mean gIQ WS (632+487) was around the estimated
cut-off of 600, but only 16.6% had a gIQ WS≥600.
Discussion
In the clinical setting, the selection of components for a salvage
regimen is a crucial issue, involving prediction of efficacy
balanced with the tolerability and acceptability of treatment.
As shown in previous studies, several factors have been associ-
ated with virological response to darunavir-based
regimens.2,7,8,10,12,14,16,22
To the best of our knowledge, this is the first study comparing
the relationship between different resistance interpretation
algorithms and their derived gIQs with virological response to
darunavir-containing salvage regimens at 48 weeks.
Among the resistance algorithms analysed, two were
weighted algorithms and five were non-weighted. Nowadays,
non-weighted algorithms are generally used for the calculation
of the gIQ, but this approach does not take into account the
different weight of the amino acid changes in the protease
gene. To date, weighted resistance algorithms have been devel-
oped only for tipranavir27,28 and for etravirine,29 with the excep-
tion of the Stanford HIVdb Program, which gives a different
weight for all the antiretroviral drugs. It is important to note
that in previous studies with tipranavir, the performance of dis-
tinct gIQs did not prove to be much more superior to that of
some genotypic resistance algorithms.30 Conversely, in our
study, the gIQ performed better than resistance mutations
alone, independent of whether they were weighted or non-
weighted. In this regard, although no apparent advantage of
using the weighted WS gIQ versus the ANRS non-weighted gIQ
was observed (as showed by the equality in parameters such
as the sensitivity, specificity, PPV, NPV, LHR+ and LHR2), the
higher area under the ROC curve of the WS gIQ led us to
choose it from among the different gIQs for the logistic
regression analysis. This highlights the importance of integrating
both pharmacological and virological data in order to obtain a
more accurate prediction of virological response, but does not
confirm the importance of the different impact of each protease
resistance mutation on virological response. Moreover, the resist-
ance algorithms that considered specific amino acid changes
associated with darunavir resistance, and their derived gIQs, pro-
vided a more accurate prediction of virological response than
non-specific algorithms. The exception is the lack of association
of the resistance score proposed in the French study PREDI-
ZISTA,22 which is in agreement with a recently published work.31
In our study, a higher rate of viral load ,50 copies/mL at
week 48 was observed (62.5%) when compared with the
Table 4. Factors associated with 48 week outcome according to virological response pattern
Null virological response (n¼3) Partial virological response (n¼18) Full virological response (n¼35) P value
Darunavir Ctrough 3261+2889 4093+1549 4914+1990 0.19*
Baseline log HIV-RNA 3.58+1.34 4.5+1.08 3.6+1.12 0.033*
D viral load 0.16+0.76 20.64+0.83 22.3+1.12 <0.0001*
POW 2.6+1.5 2.6+1.1 1.4+1.1 0.001*
WS 7+6.5 7.5+2.6 3.88+3 0.001*
WS .5 2 (66.6%) 15 (83.3%) 8 (22.8%) 0.001**
gIQ WS 437+127 632+487 2050+1675 0.002*
gIQ WS ≥600 0 (0%) 3 (16.6%) 29 (82.85%) <0.0001**
OBS 2+1 1.2+1.06 1.68+0.7 0.12*
OBS ≥2 2 (66.6%) 6 (33.3%) 23 (65.7%) 0.074**
Ctrough, trough concentration; POW, POWER trials; WS, weighted score; gIQ WS, WS genotypic inhibitory quotient; OBS, optimized background score.
Significant differences are indicated in bold (P,0.05).
*ANOVA test.
**x2 test.
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POWER trials (40%–45%).2,7 Similar rates of undetectability were
recorded in the clinical setting (59.5% at 48 weeks),16 but a
lower proportion of subjects with undetectable viral load was
recorded in the PREDIZISTA study at 12 weeks.22 A possible
explanation could be that the baseline immuno-virological
status of our population was better than in other studies. More
than 85% of our patients had less than four POW mutations,
which is the proposed cut-off of the current genotype interpret-
ation algorithm. The low number of darunavir POW resistance
mutations and the high proportion of subjects with at least
one active drug in the OBS (.87%) could explain these
differences among the studies. Moreover, only 32% of the sub-
jects in our study were classed as advanced AIDS (CDC clinical
status C) versus .50% in other studies. Due to these differences
in both virological response rates and population characteristics,
the use of the likelihood ratios seems to be the best option for
selecting the appropriate parameter, since likelihood ratios are
independent of disease prevalence.
When previous cut-offs for the resistance score and the gIQ
were analysed together with all baseline factors potentially
associated with virological response, baseline viral load, OBS
≥2, WS .5 and gIQ WS ≥600 were initially selected, but only
baseline viral load and gIQ WS ≥600 remained in the final
model. This result indicates the superior performance and useful-
ness of the gIQ over genotypic resistance alone. Several studies
have demonstrated the superiority of the virtual IQ or the real
IQ over the gIQ or the genotypic resistance profile. The disadvan-
tage of the virtual IQ or the phenotypic IQ is that its applicability
in daily clinical practice is seriously compromised, since it is not a
free-access parameter and this could compromise its applica-
bility in some outpatient clinics with low economic resources.
In our population, the darunavir Ctrough showed only a trend
toward significance (P¼0.089) as a predictor of virological
response, probably due to the low number of darunavir-specific
resistance mutations (median, 2), and a better overall immuno-
virological status, confirming previous findings from POWER trials.14
Moreover, although significant antiviral activity was initially
reached in a high number of subjects (87.5% at 4 weeks), in
.32% of subjects viral replication was not fully controlled and
a viral load rebound of more than 0.5 log occurred. The pro-
portion of subjects with significant antiviral activity gradually
decreased, being 87.5% at 4 weeks, 76.8% at 12 weeks, 67.9%
24 weeks and 62.5% at 48 weeks. In contrast, the proportion
of subjects with virological response (viral load ,50 copies/mL)
increased through follow-up, being 46.4%, 51.8%, 60.7% and
62.5% at 4, 12, 24 and 48 weeks, respectively. Although the
low number of subjects with null response (n¼3) made an accu-
rate statistical analysis impossible, a gradual increase in the gIQ
WS and the proportion of subjects above the proposed cut-off of
600 was observed among null response, partial response and full
response groups, with no differences in OBS. We can hypothesize
that although significant antiviral activity could be initially
reached with a given therapy, long-term efficacy of the treat-
ment could be maintained only at higher gIQ values, in which
maximal pharmacological pressure in relation to the specific
genotypic resistance profile is reached. In this regard, the role
of persistent low gIQ values on the development of new
protease-inhibitor resistance mutations under darunavir/ritonavir
regimens deserves further attention, although the high genetic
barrier of darunavir could overcome the effect of suboptimal
pharmacological levels. However, despite a similar OBS in the
three virological response patterns, the overall effect of the back-
ground regimen over virological response should not be underes-
timated. In fact, the interplay between the less favourable
situation in the four principal factors affecting virological
response in the partial response group (higher baseline viral
load, WS .5, OBS ≥2 and low proportion of subjects with a
gIQ WS ≥600) could lead to the loss of activity of the daruna-
vir/ritonavir-based regimen over time. Therefore, patients pre-
senting this profile at baseline with a gIQ WS close to or below
the estimated gIQ cut-off (600) could theoretically benefit
gIQ WS < 600, n = 24
gIQ WS ≥ 600, n = 36
log rank = 17.95 
P < 0.0001
WS > 5, n = 25
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Figure 2. Kaplan–Meier curve for the time of maintenance of virological
response over 48 weeks. The probability represents the proportion of
patients who presented virological failure. (a) According to De Meyer’s
mutation weighted score (WS). Patients with darunavir WS ≤5 (broken
line) or .5 (continuous line). (b) According to WS genotypic inhibitory
quotient (gIQ WS). Patients with darunavir gIQ WS ,600 (continuous
line) or ≥600 (broken line).
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under a long-term perspective by increasing the pharmacological
pressure with a darunavir dose adjustment.
Although no apparent effect of enfuvirtide administration on
virological response or viral load decrease at 48 weeks was
observed, a higher CD4+ cell count (plus 80 cells/mm3) and
CD4+ percentage increase were observed in the subset of
patients administered enfuvirtide, confirming a potential
benefit of the latter over immune recovery independent from
virological response.32
It is true that early therapeutic drug monitoring (between
weeks 4 and 12) must be performed to allow dose adjustment,
but in order to simplify the analysis and to allow the inclusion
of the maximum number of subjects, mean 48 week darunavir
Ctrough was used in the analyses. As shown in the ‘Pharmacoki-
netic analysis’ results section, the darunavir Ctrough remained
stable during the 48 week study period, and the intraindividual
variability of Ctrough was 29%, which is quite similar to that of
other protease inhibitors. Moreover, when 4 and 12 week data
were analysed (data not shown), results remained similar to
those presented at 48 weeks, being the WS by De Meyer and
its derived gIQ WS the most accurate factors predicting virologi-
cal response at 48 weeks. At these time points, the cut-offs were
very close to those obtained for 48 week parameters.
The main limitation of our study is the relatively low number
of patients. However, although this could limit the power of stat-
istical analysis performed in some subpopulations, as we pointed
out, the sample size was sufficient to draw conclusions on the
role of the different resistance algorithms and their derived gIQs.
In conclusion, this is the first study comparing different resist-
ance interpretation algorithms and their derived gIQs for the pre-
diction of 48 week virological response to darunavir-based
salvage regimens. The gIQ WS was the parameter that predicted
virological response more accurately, with a proposed cut-off of
600. Specifically, a subgroup of subjects with unfavourable base-
line characteristics (high baseline viral load, WS.5 and without
an optimal background regimen) could benefit in terms of long-
term virological response from attaining a gIQ WS much higher
than 600.
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